Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Joan MacNeill"'
Autor:
Ting-lei Gu, Julie Nardone, Yi Wang, Marc Loriaux, Judit Villén, Sean Beausoleil, Meghan Tucker, Jon Kornhauser, Jianmin Ren, Joan MacNeill, Steven P Gygi, Brian J Druker, Michael C Heinrich, John Rush, Roberto D Polakiewicz
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e19169 (2011)
Activating mutations of FMS-like tyrosine kinase-3 (FLT3) are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 is therefore an attractive drug target. However, the molecular mechanisms by which FLT3 mutations lead to cel
Externí odkaz:
https://doaj.org/article/1023d0cf89bb45dc84d23254aa8bce3c
Autor:
Ting-Lei Gu, Xiaxing Deng, Feizhou Huang, Meghan Tucker, Katherine Crosby, Victoria Rimkunas, Yi Wang, Gang Deng, Lei Zhu, Zhiping Tan, Yerong Hu, Chunlin Wu, Julie Nardone, Joan MacNeill, Jianmin Ren, Cynthia Reeves, Gregory Innocenti, Brett Norris, Jin Yuan, Jian Yu, Herbert Haack, Baiyong Shen, Chenghong Peng, Hongwei Li, Xinmin Zhou, Xunyang Liu, John Rush, Michael J Comb
Publikováno v:
PLoS ONE, Vol 6, Iss 1, p e15640 (2011)
Cholangiocarcinoma, also known as bile duct cancer, is the second most common primary hepatic carcinoma with a median survival of less than 2 years. The molecular mechanisms underlying the development of this disease are not clear. To survey activate
Externí odkaz:
https://doaj.org/article/4891caa438b14afea1b111e11dc6ac77
Autor:
Matthew P. Stokes, Anthony Possemato, Randall K. Wetzel, Jeffrey Mitchell, Michael J. Comb, Julie Nardone, Kimberly Lee, Judit Villén, Joan MacNeill, Roberto D. Polakiewicz, Jon M. Kornhauser, Gregory Innocenti, John Rush, Ailan Guo, Klarisa Rikova, Yi Wang, Steven P. Gygi
Publikováno v:
Proceedings of the National Academy of Sciences. 105:692-697
A major question regarding the sensitivity of solid tumors to targeted kinase inhibitors is why some tumors respond and others do not. The observation that many tumors express EGF receptor (EGFR), yet only a small subset with EGFR-activating mutation
Autor:
Roberto D. Polakiewicz, Cynthia Reeves, John Rush, Lana Popova, Stephen D. Nimer, Ting-Lei Gu, Julie Nardone, Joan MacNeill
Publikováno v:
Leukemia. 21:563-566
Phosphoproteomic analysis identifies the M0-91 cell line as a cellular model for the study of TEL-TRKC fusion-associated leukemia
Autor:
Roberto D. Polakiewicz, Joan MacNeill, Kimberly Lee, Erik Spek, John Rush, Albrecht Moritz, Julie Nardone, Michael J. Comb, Valerie Goss
Publikováno v:
Blood. 107:4888-4897
The Bcr-Abl fusion kinase drives oncogenesis in chronic myeloid leukemia (CML). CML patients are currently treated with the Abl tyrosine kinase inhibitor imatinib, which is effective in early stages of the disease. However, resistance to imatinib ari
Autor:
Heather Perry-O'Keefe, Shelagh Casey, James M. Coull, Brian D. Gildea, Joan MacNeill, Ditte Sørensen
Publikováno v:
Tetrahedron Letters. 39:7255-7258
Fmoc-protected hydrophilic amino acids were prepared and incorporated into peptide nucleic acid (PNA). N- and C-terminal modification of PNA did not affect its ability to hybridize to complementary nucleic acid targets as determined by dot blot, PNA-
Autor:
Valerie L. Goss, Cynthia Reeves, Michael J. Comb, Lana Popova, Brian J. Druker, Julie Nardone, Roberto D. Polakiewicz, Denise K. Walters, Joan MacNeill, John Edward Rush, Yi Wang, Ting-Lei Gu
Publikováno v:
Blood. 108:4202-4204
The 8p11 myeloproliferative syndrome (EMS) is associated with translocations that disrupt the FGFR1 gene. To date, 8 fusion partners of FGFR1 have been identified. However, no primary leukemia cell lines were identified that contain any of these fusi
Autor:
Zhi-Ping Tan, Herbert Haack, Xinmin Zhou, Yi Wang, Gregory Innocenti, Xiaxing Deng, Hongwei Li, John Rush, Meghan Ann Tucker, Baiyong Shen, Cynthia Reeves, Julie Nardone, Jian Yu, Yerong Hu, Lei Zhu, Brett Norris, Victoria Rimkunas, Joan MacNeill, Jin Yuan, Xunyang Liu, Michael J. Comb, Gang Deng, Jianmin Ren, Ting-Lei Gu, Chenghong Peng, Feizhou Huang, Chun-Lin Wu, Katherine Crosby
Publikováno v:
PLoS ONE, Vol 6, Iss 1, p e15640 (2011)
PLoS ONE
PLoS ONE
Cholangiocarcinoma, also known as bile duct cancer, is the second most common primary hepatic carcinoma with a median survival of less than 2 years. The molecular mechanisms underlying the development of this disease are not clear. To survey activate
Autor:
Peter Hornbeck, John Rush, Jing Zhou, Steven P. Gygi, Michael J. Comb, Jian Min Ren, Judit Villén, Albrecht Moritz, Yu Li, Kam Sprott, Ailan Guo, Anthony Possemato, Jon M. Kornhauser, Lewis C. Cantley, Yi Wang, Joan MacNeill
Publikováno v:
Science signaling. 3(136)
Receptor tyrosine kinases (RTKs) activate pathways mediated by serine-threonine kinases, such as the PI3K (phosphatidylinositol 3-kinase)-Akt pathway, the Ras-MAPK (mitogen-activated protein kinase)-RSK (ribosomal S6 kinase) pathway, and the mTOR (ma
Autor:
Steven P. Gygi, Joan MacNeill, Kam Sprott, Michael J. Comb, Matthew P. Stokes, Roberto D. Polakiewicz, Jian Min Ren, Julie Nardone, Mark Livingstone, Sean A. Beausoleil, Hui Zhang, John Rush, Vicky Yang
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 104(50)
To ensure survival in the face of genomic insult, cells have evolved complex mechanisms to respond to DNA damage, termed the DNA damage checkpoint. The serine/threonine kinases ataxia telangiectasia-mutated (ATM) and ATM and Rad3-related (ATR) activa